- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02325362
Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation (MIGLUSTAT-CF)
March 16, 2018 updated by: Assistance Publique - Hôpitaux de Paris
Single Center, Double-blind, Randomized, Placebo-controlled, Two-period/Two-treatment Crossover, Proof-of-mechanism Study Investigating the Effect of Miglustat on the Nasal Potential Difference in Adult Patients With Cystic Fibrosis Homozygous for the F508del Mutation
The purpose of this study is to demonstrate that Miglustat restores the function of the cystic fibrosis transmembrane conductance regulator (CFTR) in adult patients with cystic fibrosis homozygous for the F508del mutation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The aims of this study are:
- To determine whether Miglustat can restore the function of the CFTR protein in adult patients with cystic fibrosis homozygous for the F508del mutation
- To evaluate the safety, tolerability and pharmacokinetics of Miglustat in adult patients with cystic fibrosis homozygous for the F508del mutation.
- To investigate pharmacokinetic-pharmacodynamic of Miglustat in adult patients with cystic fibrosis homozygous for the F508del mutation.
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Paris, France, 75014
- Assistance publique-Hôpitaux de Paris, Hôpital Cochin
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Inclusion criteria at screening visit (Visit 1):
- Aged 18 years and older
- Male or female
Women of childbearing potential must:
- have a negative serum pregnancy test at Visit 1
- agree to use from Visit 1 until 3 months after the last study drug intake a reliable method of contraception
- Male patients accepting for the duration of the study and for 3 months thereafter to use a condom
- Homozygous for the F508del mutation as confirmed by genetic testing
- Sweat chloride ≥ 60 mmol/L
- Basal nasal potential difference (NPD) ≤ -30.0 mV (equal to or more electrically negative than -30.0 mV) and total chloride secretion (TCS) ≥ - 5.0 mV for at least one nostril. However, if it is possible to analyze both nostrils, the total chloride secretion (TCS) is to be ≥ - 5.0 mV (equal to or more electrically positive than - 5.0 mV) in both nostrils.
- FEV1 ≥ 25% of predicted
- Able to comply with all protocol requirements
- Signed informed consent prior to any study-mandated procedure
Inclusion criteria at randomization visit (Visit 2):
- Women of child-bearing potential must have a negative urine pregnancy test
- Basal nasal potential difference (NPD) ≤ - 30.0 mV (equal to or more electrically negative than - 30.0 mV) and total chloride secretion (TCS) ≥ - 5.0 mV for at least one nostril. However, if it is possible to analyze both nostrils, the total chloride secretion (TCS) is to be ≥ - 5.0 mV (equal to or more electrically positive than - 5.0 mV) in both nostrils.
Exclusion Criteria:
- Any condition prohibiting the correct measurement of the NPD such as upper respiratory tract infection
- Acute upper or lower respiratory tract infection requiring antibiotic intervention within 2 weeks of screening
- Lung transplant recipient or patient on a lung transplant waiting list
- Any modification in regular treatments (new treatment initiated or discontinued treatment) or modification in dosing within 2 weeks prior to start of Period 1
- Moderate/Severe renal impairment (creatinine clearance < 70 mL/min as per Cockroft and Gault)
- Systemic corticosteroids (> 10 mg/day prednisone or equivalent) within 14 days prior to screening and up to start of study
- Women who are breast-feeding, pregnant, or who plan to become pregnant during the course of the study
- History of significant lactose intolerance
- Presence of clinically significant diarrhoea (> 3 liquid stools per day for > 7 days) without definable cause within one month prior to screening
- Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as drug or alcohol dependence or psychiatric disease
- Active or passive smoking
- Hypersensitivity to Miglustat or any excipients
- Planned treatment or treatment with another investigational drug or therapy (e.g., gene therapy) within one month prior to randomization
- Known concomitant life-threatening disease with a life expectancy < 12 months
- Indication against Isuprel® (Isoproterenol) including heart diseases.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Miglustat then placebo
10 patients will received Miglustat then the placebo
|
For this 2 x 2 (2 periods /2 treatments) crossover design each patient will receive Miglustat during the first period (2 weeks), following by a wash out period(14 days (up to 4 weeks)), then Placebo during the second period (2 weeks).
30 days follow-up will be carried out after end-of-treatment of the second period.
|
Experimental: Placebo then Miglustat
10 patients will received Placebo then Miglustat
|
For this 2 x 2 (2 periods /2 treatments) crossover design each patient will receive Placebo during the first period (2 weeks), following by wash out period (14 days (up to 4 weeks)), then Miglustat during the second period (2 weeks).
30 days follow-up will be carried out after end of treatment of the second period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean TCS in mV
Time Frame: day 1
|
TCS (Total Chloride Secretion) is the sum of responses in nasal potential difference (NPD) calculated as the mean of the right and left nostril measurements for each patient
|
day 1
|
Mean TCS in mV
Time Frame: Day 14
|
TCS (Total Chloride Secretion) is the sum of responses in nasal potential difference (NPD) calculated as the mean of the right and left nostril measurements for each patient
|
Day 14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
TCS difference in mV
Time Frame: day 1
|
TCS difference is calculated as the change in measurements of TCS for the right and left nostrils independently for each patient.
|
day 1
|
TCS difference in mV
Time Frame: Day 14
|
TCS difference is calculated as the change in measurements of TCS for the right and left nostrils independently for each patient.
|
Day 14
|
Percentage of patients with a TCS response to treatment ≤ - 5 mV
Time Frame: day 1
|
The percentage of patients with a TCS response to treatment defined as a difference in TCS from baseline to end-of-treatment ≤ -5mV
|
day 1
|
Percentage of patients with a TCS response to treatment ≤ - 5 mV
Time Frame: day 14
|
The percentage of patients with a TCS response to treatment defined as a difference in TCS from baseline to end-of-treatment ≤ -5mV
|
day 14
|
Percentage of patients with a TCS at end-of-treatment ≤ - 5 mV
Time Frame: day 1
|
The percentage of patients with a TCS response at end-of-treatment ≤ -5mV
|
day 1
|
Percentage of patients with a TCS at end-of-treatment ≤ - 5 mV
Time Frame: day 14
|
The percentage of patients with a TCS response at end-of-treatment ≤ -5mV
|
day 14
|
Change of basal NPD in mV
Time Frame: day 1
|
Basal NPD at end-of-treatment minus basal NPD at baseline
|
day 1
|
Change of basal NPD in mV
Time Frame: day 14
|
Basal NPD at end-of-treatment minus basal NPD at baseline
|
day 14
|
Change of the response in NPD after superfusion with amiloride
Time Frame: day 1
|
NPD after superfusion with amiloride at end-of-treatment minus NPD after superfusion with amiloride at baseline
|
day 1
|
Change of the response in NPD after superfusion with amiloride
Time Frame: day 14
|
NPD after superfusion with amiloride at end-of-treatment minus NPD after superfusion with amiloride at baseline
|
day 14
|
Change of the response in NPD after superfusion with a chloride-free buffer in the presence of amiloride
Time Frame: day 1
|
NPD after superfusion with a chloride-free buffer in the presence of amiloride at end-of-treatment minus NPD after superfusion with a chloride-free buffer in the presence of amiloride at baseline
|
day 1
|
Change of the response in NPD after superfusion with a chloride-free buffer in the presence of amiloride
Time Frame: day 14
|
NPD after superfusion with a chloride-free buffer in the presence of amiloride at end-of-treatment minus NPD after superfusion with a chloride-free buffer in the presence of amiloride at baseline
|
day 14
|
Wilschanski's index change
Time Frame: day 1
|
Wilschanski's index is defined as (exposant(response to Chloride-free and isoproterenol/response amiloride)): Wilschanski's index at end-of-treatment minus Wilschanski's at baseline
|
day 1
|
Wilschanski's index change
Time Frame: day 14
|
Wilschanski's index is defined as (exposant(response to Chloride-free and isoproterenol/response amiloride)): Wilschanski's index at end-of-treatment minus Wilschanski's at baseline
|
day 14
|
Sweat chloride concentration in mmol/L
Time Frame: day 1
|
Sweat chloride concentration at end-of-treatment minus sweat chloride concentration at baseline
|
day 1
|
Sweat chloride concentration in mmol/L
Time Frame: day 14
|
Sweat chloride concentration at end-of-treatment minus sweat chloride concentration at baseline
|
day 14
|
FEV1 (in % of predicted)
Time Frame: day 1
|
Pulmonary function FEV1: mean Forced expiry volume in 1 second.
FEV1 at end-of-treatment minus FEV1 at baseline
|
day 1
|
FEV1 (in % of predicted)
Time Frame: day 14
|
Pulmonary function FEV1: mean Forced expiry volume in 1 second.
FEV1 at end-of-treatment minus FEV1 at baseline
|
day 14
|
Change in electrochemical skin conductance
Time Frame: day 1
|
Electrochemical skin conductance at end-of-treatment minus electrochemical skin conductance at baseline
|
day 1
|
Change in electrochemical skin conductance
Time Frame: day 14
|
Electrochemical skin conductance at end-of-treatment minus electrochemical skin conductance at baseline
|
day 14
|
Number of cells expressing CFTR at the cell membrane (in %percentage)
Time Frame: day 14
|
Percentage of nasal cells expressing CFTR at the cell membrane as assessed by immunochemistry and confocal microscopy
|
day 14
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Isabelle FAJAC, MD, PhD., Assistance Publique - Hôpitaux de Paris
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 17, 2015
Primary Completion (Actual)
April 3, 2017
Study Completion (Actual)
April 3, 2017
Study Registration Dates
First Submitted
December 10, 2014
First Submitted That Met QC Criteria
December 19, 2014
First Posted (Estimate)
December 25, 2014
Study Record Updates
Last Update Posted (Actual)
March 19, 2018
Last Update Submitted That Met QC Criteria
March 16, 2018
Last Verified
March 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Respiratory Tract Diseases
- Lung Diseases
- Infant, Newborn, Diseases
- Genetic Diseases, Inborn
- Pancreatic Diseases
- Fibrosis
- Cystic Fibrosis
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Glycoside Hydrolase Inhibitors
- Miglustat
- 1-Deoxynojirimycin
Other Study ID Numbers
- P120703
- 2013-000497-29 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystic Fibrosis
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
University of Colorado, DenverCystic Fibrosis FoundationTerminatedCystic Fibrosis-related Diabetes | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in ChildrenUnited States
-
Royal College of Surgeons, IrelandThe Hospital for Sick Children; Imperial College London; Erasmus Medical Center; University College Dublin and other collaboratorsActive, not recruitingCystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver DiseaseUnited Kingdom, Ireland
-
Herlev and Gentofte HospitalCopenhagen University Hospital, DenmarkActive, not recruitingMyocardial Infarction | Heart Diseases | Heart Failure | Stroke | Cystic Fibrosis | Heart Failure, Diastolic | Heart Failure, Systolic | Left Ventricular Dysfunction | Cystic Fibrosis-related Diabetes | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of Pancreas | Cystic Fibrosis, Pulmonary | Cystic...Denmark
-
The Hospital for Sick ChildrenCanadian Cystic Fibrosis FoundationActive, not recruitingCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in ChildrenCanada
-
Arrowhead PharmaceuticalsTerminatedCystic Fibrosis, PulmonaryAustralia, New Zealand
-
AzurRx SASCompletedCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of PancreasTurkey, Hungary
-
Dartmouth-Hitchcock Medical CenterTrustees of Dartmouth CollegeWithdrawnCystic Fibrosis-related Diabetes | Cystic Fibrosis Liver Disease | CF - Cystic FibrosisUnited States
-
University of PortsmouthUniversity Hospital Southampton NHS Foundation Trust; Loughborough University; Queen Alexandra HospitalTerminated
-
University Hospital, BordeauxCompleted
Clinical Trials on Miglustat ; placebo
-
ActelionCompleted
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedContraceptionUnited States
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaboratorsTerminatedTay-Sachs Disease | Sandhoff Disease | GM1 Gangliosidoses | GM2 GangliosidosesUnited States
-
The Hospital for Sick ChildrenActelionCompletedGangliosidoses GM2Canada
-
Children's National Research InstituteActelionCompletedSandhoff Disease | GM2 Gangliosidoses | Tay-SachsUnited States
-
IRCCS Fondazione Stella MarisCompletedHereditary Spastic ParaparesisItaly
-
University of FloridaAmicus TherapeuticsTerminatedPompe Disease | Hypersensitivity Reaction
-
Beyond Batten Disease FoundationTheranexusActive, not recruitingBatten DiseaseUnited States